Skip to main content
Figure 1 | Molecular Cancer

Figure 1

From: Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

Figure 1

TOV21G p53 positive and negative matched pair cell lines treated with gemcitabine and Wee1 inhibitor. TOV21G positive- and negative cell lines were treated with 30 nM gemcitabine, and 100 and 300 nM of the Wee1 inhibitor. At 8 hr post Wee1 inhibitor treatment, cells were subjected to flow cytometry analysis. The percentage of the subG1 fraction corresponds to apoptotic cells. TOV21G-Vec: wild-type p53 cells; TOV21G-shp53: p53-deficient cells; Gem: gemcitabine. **, P < 0.01, compared with TOV21G-Vec.

Back to article page

Molecular Cancer

ISSN: 1476-4598